A Clinical Trial of Antiplatelets in Psoriasis
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-90
SponsorNYU Langone Health
About this trial
The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.
Eligibility criteria
Qualifiers
A history of psoriasis as confirmed by a board-certified dermatologist OR
A history of psoriatic arthritis as confirmed by a board-certified rheumatologist
Age ≥ 18 & < 90 years
Able and willing to provide written informed consent for the study
Disqualifiers
A prior history of a myocardial infarction, stroke/TIA, or occlusive peripheral arterial disease
Chronic antiplatelet/anticoagulant use that is not able to be stopped at least 14 days prior to study enrollment
Uncontrolled hypertension resting systolic blood pressure > 180 mm Hg or diabetes HbA1c > 10%
Known active cancer receiving treatment
Trial design
Treatments tested in this trial
- Aspirin
- Clopidogrel
- Placebo
Treatment groups
60 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
NYU Langone Health
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov